ATR
Basic information
Region (hg38): 3:142449007-142578733
Links
Phenotypes
GenCC
Source:
- Seckel syndrome 1 (Strong), mode of inheritance: AR
- sarcoma (Moderate), mode of inheritance: AD
- familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome (Moderate), mode of inheritance: AD
- Seckel syndrome (Supportive), mode of inheritance: AR
- familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome (Supportive), mode of inheritance: AD
- Seckel syndrome 1 (Definitive), mode of inheritance: AR
- familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cutaneous telangiectasia and cancer syndrome, familial; Seckel syndrome 1 | AD/AR | Oncologic | Though both Seckel syndrome 1 and Cutaneous telangiectasia and cancer syndrome, familial are potentially recognizable, surveillance and/or awareness of cancer risk may allow early diagnosis and treatment of oncologic manifestations, which may reduce morbidity and mortality | Craniofacial; Dental; Dermatologic; Musculoskeletal; Neurologic; Oncologic | 13869653; 6022184; 4378248; 7046443; 8358044; 8182723; 9128935; 10889046; 12640452; 22341969; 23111928; 30199583; 30846821 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (62 variants)
- Seckel syndrome 1 (3 variants)
- Inborn genetic diseases (2 variants)
- Endometrium neoplasm (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ATR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 16 | 962 | 985 | |||
missense | 1717 | 27 | 1752 | |||
nonsense | 24 | 31 | ||||
start loss | 1 | |||||
frameshift | 37 | 43 | ||||
inframe indel | 11 | 11 | ||||
splice donor/acceptor (+/-2bp) | 16 | 21 | ||||
splice region | 44 | 65 | 5 | 114 | ||
non coding | 14 | 266 | 71 | 352 | ||
Total | 64 | 25 | 1767 | 1255 | 85 |
Highest pathogenic variant AF is 0.0000399
Variants in ATR
This is a list of pathogenic ClinVar variants found in the ATR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-142449134-A-G | Benign (Jun 16, 2018) | |||
3-142449327-G-A | Seckel syndrome 1 | Uncertain significance (Jan 12, 2018) | ||
3-142449357-A-C | Seckel syndrome 1 | Uncertain significance (Jan 13, 2018) | ||
3-142449433-A-G | Inborn genetic diseases | Uncertain significance (Aug 24, 2022) | ||
3-142449438-T-C | Inborn genetic diseases | Likely benign (Oct 15, 2022) | ||
3-142449440-G-C | Inborn genetic diseases | Uncertain significance (Apr 15, 2023) | ||
3-142449442-G-A | Uncertain significance (Jan 02, 2022) | |||
3-142449451-A-G | Inborn genetic diseases | Uncertain significance (Mar 31, 2023) | ||
3-142449452-G-A | Uncertain significance (Nov 27, 2023) | |||
3-142449458-T-A | Inborn genetic diseases | Uncertain significance (Jan 25, 2023) | ||
3-142449462-G-A | Inborn genetic diseases • Seckel syndrome 1;Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome • Seckel syndrome 1 • Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | Likely benign (Jan 13, 2024) | ||
3-142449464-A-C | Inborn genetic diseases | Uncertain significance (Dec 14, 2023) | ||
3-142449465-T-C | not specified • Inborn genetic diseases • Seckel syndrome 1 • Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | Likely benign (Dec 13, 2023) | ||
3-142449468-T-A | Inborn genetic diseases | Uncertain significance (Jul 30, 2023) | ||
3-142449470-A-C | Inborn genetic diseases | Uncertain significance (Dec 15, 2021) | ||
3-142449470-A-G | Inborn genetic diseases | Likely benign (Jun 18, 2022) | ||
3-142449471-G-C | Inborn genetic diseases | Uncertain significance (May 05, 2023) | ||
3-142449474-T-C | Inborn genetic diseases | Likely benign (Dec 04, 2020) | ||
3-142449477-A-T | Inborn genetic diseases | Uncertain significance (Mar 15, 2024) | ||
3-142449479-C-G | Inborn genetic diseases | Uncertain significance (Jun 10, 2022) | ||
3-142449479-C-T | Inborn genetic diseases | Uncertain significance (May 07, 2022) | ||
3-142449480-A-G | Inborn genetic diseases | Likely benign (Dec 18, 2022) | ||
3-142449489-C-T | not specified • Seckel syndrome 1 • Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | Benign/Likely benign (Feb 01, 2024) | ||
3-142449493-A-G | Inborn genetic diseases | Uncertain significance (Jun 08, 2024) | ||
3-142449500-A-G | Seckel syndrome 1 • Inborn genetic diseases • Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | Uncertain significance (Feb 01, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ATR | protein_coding | protein_coding | ENST00000350721 | 47 | 129592 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.52e-9 | 1.00 | 125524 | 1 | 223 | 125748 | 0.000891 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.36 | 915 | 1.37e+3 | 0.668 | 0.0000687 | 17423 |
Missense in Polyphen | 247 | 544.68 | 0.45347 | 6918 | ||
Synonymous | 0.804 | 458 | 480 | 0.953 | 0.0000239 | 4949 |
Loss of Function | 7.55 | 43 | 139 | 0.309 | 0.00000770 | 1713 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00145 | 0.00143 |
Ashkenazi Jewish | 0.0000993 | 0.0000992 |
East Asian | 0.000707 | 0.000707 |
Finnish | 0.000324 | 0.000323 |
European (Non-Finnish) | 0.000459 | 0.000448 |
Middle Eastern | 0.000707 | 0.000707 |
South Asian | 0.00367 | 0.00363 |
Other | 0.000816 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication. {ECO:0000269|PubMed:10597277, ECO:0000269|PubMed:10608806, ECO:0000269|PubMed:10859164, ECO:0000269|PubMed:11114888, ECO:0000269|PubMed:11418864, ECO:0000269|PubMed:11673449, ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:11865061, ECO:0000269|PubMed:12526805, ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:12814551, ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:14742437, ECO:0000269|PubMed:15210935, ECO:0000269|PubMed:15314022, ECO:0000269|PubMed:15496423, ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9636169, ECO:0000269|PubMed:9925639}.;
- Disease
- DISEASE: Seckel syndrome 1 (SCKL1) [MIM:210600]: A rare autosomal recessive disorder characterized by proportionate dwarfism of prenatal onset associated with low birth weight, growth retardation, severe microcephaly with a bird-headed like appearance, and mental retardation. {ECO:0000269|PubMed:12640452}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) [MIM:614564]: A disease characterized by cutaneous telangiectases in infancy with patchy alopecia over areas of affected skin, thinning of the lateral eyebrows, and mild dental and nail anomalies. Affected individuals are at increased risk of developing oropharyngeal cancer, and other malignancies have been reported as well. {ECO:0000269|PubMed:22341969}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Fanconi anemia pathway - Homo sapiens (human);Cell cycle - Homo sapiens (human);p53 signaling pathway - Homo sapiens (human);HTLV-I infection - Homo sapiens (human);Cellular senescence - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);Cell Cycle;miRNA Regulation of DNA Damage Response;TP53 Regulates Transcription of DNA Repair Genes;ATR Signaling;ATM Signaling Network in Development and Disease;DNA Damage Response;HDR through Single Strand Annealing (SSA);HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA);Fanconi Anemia Pathway;DNA Repair;Gene expression (Transcription);DNA Double-Strand Break Repair;role of brca1 brca2 and atr in cancer susceptibility;cell cycle: g1/s check point;regulation of cell cycle progression by plk3;Generic Transcription Pathway;Regulation of HSF1-mediated heat shock response;Homology Directed Repair;Cellular responses to stress;Reproduction;RNA Polymerase II Transcription;G2/M DNA damage checkpoint;Activation of ATR in response to replication stress;G2/M Checkpoints;Cell Cycle Checkpoints;Meiotic synapsis;Meiosis;cell cycle: g2/m checkpoint;Cellular responses to external stimuli;atm signaling pathway;TP53 Regulates Transcription of DNA Repair Genes;Fanconi anemia pathway;Cellular response to heat stress;Regulation of TP53 Activity through Phosphorylation;Regulation of TP53 Activity;Transcriptional Regulation by TP53;Cell Cycle;Circadian rhythm pathway;BARD1 signaling events;Processing of DNA double-strand break ends;ATR signaling pathway;p53 pathway;Presynaptic phase of homologous DNA pairing and strand exchange;Homologous DNA Pairing and Strand Exchange;HDR through Homologous Recombination (HRR)
(Consensus)
Recessive Scores
- pRec
- 0.143
Intolerance Scores
- loftool
- 0.718
- rvis_EVS
- -1.64
- rvis_percentile_EVS
- 2.79
Haploinsufficiency Scores
- pHI
- 0.813
- hipred
- Y
- hipred_score
- 0.719
- ghis
- 0.617
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.846
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Atr
- Phenotype
- pigmentation phenotype; neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; skeleton phenotype; renal/urinary system phenotype; immune system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype;
Zebrafish Information Network
- Gene name
- atr
- Affected structure
- head
- Phenotype tag
- abnormal
- Phenotype quality
- decreased size
Gene ontology
- Biological process
- DNA damage checkpoint;telomere maintenance;DNA replication;DNA repair;cellular response to DNA damage stimulus;multicellular organism development;negative regulation of DNA replication;peptidyl-serine phosphorylation;positive regulation of telomere maintenance via telomerase;cellular response to UV;interstrand cross-link repair;response to drug;positive regulation of DNA damage response, signal transduction by p53 class mediator;protein autophosphorylation;protein localization to chromosome, telomeric region;cellular response to gamma radiation;replicative senescence;establishment of RNA localization to telomere;establishment of protein-containing complex localization to telomere;regulation of cellular response to heat;positive regulation of telomerase catalytic core complex assembly
- Cellular component
- nuclear chromosome, telomeric region;nucleus;nucleoplasm;chromosome;Golgi apparatus;PML body
- Molecular function
- DNA binding;protein kinase activity;protein serine/threonine kinase activity;protein binding;ATP binding;MutLalpha complex binding;MutSalpha complex binding